Sayson, Khimberlie .

HRN: 26-18-59  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/09/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/09/2024
11/10/2024
IVT
500mg
Q8
Thickly Msaf
Waiting Final Action 
11/10/2024
CEFUROXIME 1.5GM (VIAL)
11/10/2024
11/11/2024
IV
1.5g
Q8
S/p CS
Waiting Final Action 
11/10/2024
CEFUROXIME 500MG (TAB)
11/11/2024
11/18/2024
PO
500mg
BID
S/p CS
Waiting Final Action 
11/10/2024
CEFUROXIME 500MG (TAB)
11/10/2024
11/16/2024
PO
500 Mg Tab
BID
SP LTCS
Waiting Final Action 
11/10/2024
METRONIDAZOLE 500MG (TAB)
11/10/2024
11/16/2024
PO
500 Mg Tab
TID
SP LTCS
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: